Koyfin Home > Directory > Health Care > Acorda Therapeutics > EV / EBITDA (ntm)

Acorda Therapeutics EV / EBITDA (ntm) Chart (ACOR)

Acorda Therapeutics annual/quarterly EV / EBITDA (ntm) from 2010 to 2020. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the next twelve months (NTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Acorda Therapeutics EV / EBITDA (ntm) for the quarter ending May 05, 2020 was 15.17 a -0.64% decrease of -0.10 year over year
  • Acorda Therapeutics EV / EBITDA (ntm) for the last 12 months ending May 05, 2020 was 15.17 a -0.64% decrease of -0.10 year over year
  • Acorda Therapeutics Annual EV / EBITDA (ntm) for 2020 was 15.17 a 1.14% increase of 0.17 from 2019
  • Acorda Therapeutics Annual EV / EBITDA (ntm) for 2020 was 15.00 a 0.22% increase of 0.03 from 2019
  • Acorda Therapeutics Annual EV / EBITDA (ntm) for 2020 was 14.97 a -2.02% decrease of -0.30 from 2019
Other Valuation Metrics:
  • Acorda Therapeutics Market Cap for the quarter ending March 03, 2018 was $1,110m a 17.15% increase of 190m year over year
  • Acorda Therapeutics Price / Book for the quarter ending March 03, 2018 was 2.11 a 35.48% increase of 0.75 year over year
  • Acorda Therapeutics Enterprise Value for the quarter ending March 03, 2018 was $1,138m a 2.19% increase of 25m year over year
View Chart On Koyfin

Quarterly ACOR EV / EBITDA (ntm) Data

05/202015.17
05/202015.00
05/202014.97
04/202015.27
04/202015.60
04/202015.43
04/202015.65
04/202015.58
04/202015.73
04/202015.82

Annual ACOR EV / EBITDA (ntm) Data

202015.17
202015.00
202014.97
202015.27
202015.60
202015.43
202015.65
202015.58
202015.73
202015.82